2970 Wilderness Place
109 articles with Biodesix, Inc.
Biodesix Announces Data from Three Studies on Lung Nodule Diagnosis and Management to be Shared at CHEST Annual Meeting 2020
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, recently published data from three clinical studies, which found important new information on diagnosis and management of lung nodules.
Addario Lung Cancer Medical Institute and Biodesix Initiate Prospective Study to Predict Overall Survival Using Checkpoint Immunotherapy for Front-Line Lung Cancer in Patients with High PDL1 Expression
Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers, including the proteomic Primary Immune Response (PIR) test, for front-line non-small cell lung cancer (NSCLC) patients receiv
Biodesix, Inc. , a leading diagnostic company with a focus in lung disease, today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24. “The health and safety of our nation’s students, and the faculty and staff that teach, guide, an
Biodesix, Inc. a leader in lung cancer diagnostics, announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors.
Biodesix Pipeline Test Identifies Patients Who Are Likely to Respond to Immune Checkpoint Inhibitors
Biodesix, Inc., a leader in lung cancer diagnostics, announced the publication of research findings on a diagnostic test capable of generating valuable data to help guide the treatment of patients with advanced non-small cell lung cancer.
Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.
Range of Testing Solutions Aimed at Helping Businesses Safely Resume Work Operations
Clinical Data Offer Meaningful Diagnostic Information for Patients in the Lung Cancer Continuum of Care
Biodesix, Inc., a leading diagnostic company in lung disease, announced that it has partnered with Boulder Community Health, a community owned-and-operated not-for-profit health system, to offer expanded COVID-19 testing in the greater Boulder, CO area.
Biodesix Collaborates With Bio-Rad to Launch a Serology Test to Detect Coronavirus (COVID-19) Antibodies
Biodesix, Inc., a leading diagnostic company in lung disease, announced that it has collaborated with Bio-Rad Laboratories, Inc. to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.
Droplet Digital™ PCR Test Offered for Detection of SARS-CoV-2
Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.
Data show Droplet Digital™ PCR Test Can Detect COVID-19 with Greater Sensitivity and Precision
New Structure Increases Customer Focus, Agility and Growth Opportunities
Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDTTM test, designed to help physicians identify patients with lung nodules at high risk of lung cancer.
Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY.
Biodesix, Inc. and Streck, Inc. today announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).
Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association (CBSA). The company was honored at the 16th Annual CBSA Awards Dinner on November 7, 2019.
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML
AVEO Oncology and Biodesix, Inc. announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia.
Former CEO David Brunel to Serve as Chairman of the Board of Directors